<DOC>
	<DOC>NCT01135069</DOC>
	<brief_summary>The objective will be to assess clinical bioequivalence of 0.1% Retin-A Micro® Gel and Spear Pharmaceutical's generic 0.1% Tretinoin Microsphere Gel with a placebo arm.</brief_summary>
	<brief_title>Bioequivalence Study of Generic Tretinoin 0.1% Microsphere Gel, 0.1% Retin-A Micro® and Placebo</brief_title>
	<detailed_description>Not required</detailed_description>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>Normal, healthy male and female children and adult Written and verbal informed consent must be obtained. Patients age 12 to 17 (inclusive) must sign an assent for the study and a parent or a legal guardian must sign the informed consent. Women of childbearing potential must be nonpregnant and nonnursing, and must be willing to avoid pregnancy during the course of the study and during the menstrual cycle following completion of their participation in the study. Able to refrain from the use of all other topical acne medications or antibiotics during the treatment period. Considered reliable and capable of understanding their responsibility and role in the study. Significant history or clinical evidence of autoimmune, cardiovascular, gastrointestinal, hematological, hepatic, neurological, pancreatic, or renal disease. Abnormal preexisting skin condition which might affect the normal course of acne vulgaris (e.g., eczema, psoriasis, albinism, or chronic vesiculobullous disorders). Use topical acne therapy during the two week period prior to study initiation. Use of systemic retinoid treatment within six months prior to study initiation. Pregnant or breastfeeding. Serious psychological illness. Participation in any clinical research study during the 30 day period preceding study initiation.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>